Attovia Therapeutics announced positive topline results from its Phase 1b study of ATTO-1310 for chronic pruritus and atopic dermatitis, showing good tolerability and sustained itch reduction. This successful early-stage trial paves the way for two Phase 2 trials in early 2027, indicating significant progress for the company's pipeline.
Attovia Therapeutics reported positive topline results from its Phase 1b study of ATTO-1310, a drug targeting chronic pruritus and high-itch atopic dermatitis. The study demonstrated that ATTO-1310 was well-tolerated and achieved sustained IL-31 suppression, leading to a rapid and sustained reduction in itch. This is a significant positive development for Attovia as it validates their lead candidate and provides a clear path forward for advancement into two Phase 2 trials in the first half of 2027. For traders, this news presents a short-term opportunity for a positive stock reaction for Attovia, and long-term, it de-risks a key pipeline asset, potentially increasing the company's valuation and attractiveness for future investment or partnerships. The key risk is the success of the upcoming Phase 2 trials, which will be larger and more rigorous.